Drug Safety

, Volume 16, Issue 6, pp 355–365

Principles of Signal Detection in Pharmacovigilance

  • Ronald H. B. Meyboom
  • Antoine C. G. Egberts
  • I. Ralph Edwards
  • Yechiel A. Hekster
  • Fred H. P. de Koning
  • Frank W. J. Gribnau
Leading Article

Summary

Adverse drug effects are manifold and heterogenous. Many situations may hamper the signalling (i.e. the detection of early warning signs) of adverse effects and new signals often differ from previous experiences.

Signals have qualitative and quantitative aspects. Different categories of adverse effects need different methods for detection. Current pharmacovigilance is predominantly based on spontaneous reporting and is mainly helpful in detecting type B effects (those effects that are often allergic or idiosyncratic reactions, characteristically occurring in only a minority of patients and usually unrelated to dosage and that are serious, unexpected and unpredictable) and unusual type A effects (those effects that are related to the pharmacological effects of the drug and are dosage-related). Examples of other sources of signals are prescription event monitoring, large automated data resources on morbidity and drug use (including record linkage), case-control surveillance and follow-up studies. Type C effects (those effects related to an increased frequency of ‘spontaneous’ disease) are difficult to study, however, and continue to pose a pharmacoepidemiological challenge.

Seven basic considerations can be identified that determine the evidence contained in a signal: quantitative strength of the association, consistency of the data, exposure response relationship, biological plausibility, experimental findings, possible analogies and the nature and quality of the data. A proposal is made for a standard signal management procedure at pharmacovigilance centres, including the following steps: signal delineation, literature search, preliminary inventory of data, collection of additional information, consultation with the World Health Organization Centre for International Drug Monitoring and the relevant drug companies, aggregated data assessment and a report in writing. A better understanding of the conditions and mechanisms involved in the detection of adverse drug effects may further improve strategies for pharmacovigilance.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Inman WHW, editor. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press, 1986Google Scholar
  2. 2.
    Strom BL, editor. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley, 1994Google Scholar
  3. 3.
    Irey N. Tissue reactions to drugs. Am J Pathol 1976; 82: 617–47Google Scholar
  4. 4.
    Evans SA. Causation and disease: the Henle-Koch postulates revisited. Yale J Biol Med 1976; 49: 175–95PubMedGoogle Scholar
  5. 5.
    Inman B. 30 years in postmarketing surveillance: a personal perspective. Pharmacoepidemiol Drug Saf 1993; 2: 239–58CrossRefGoogle Scholar
  6. 6.
    Inman WHW. Postmarketing surveillance of adverse drug reactions in general practice. BMJ 1981; 282: 1131–2PubMedCrossRefGoogle Scholar
  7. 7.
    Jick H. The discovery of drug-induced illness. N Engl J Med 1977; 296: 481–5PubMedCrossRefGoogle Scholar
  8. 8.
    Davies DM, editor. Textbook of adverse drug reactions. 4th ed. Oxford: Oxford University Press, 1991Google Scholar
  9. 9.
    Edwards R, Lindquist M, Wiholm BE, et al. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990; 336: 156–8PubMedCrossRefGoogle Scholar
  10. 10.
    Coulter DM, Edwards IR, McQueen EG. New Zealand. In: Inman WHW, editor. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press, 1986: 119–33Google Scholar
  11. 11.
    Dunne JF. The World Health Organization. In: Inman WHW, editor. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press, 1986: 165–72Google Scholar
  12. 12.
    Wiholm BE, Olsson S, Moore N, et al. Spontaneous reporting systems outside the United States. In: Strom BL, editor. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley, 1994Google Scholar
  13. 13.
    Li D, Lindquist M, Edwards IR. Evaluation of early signals of drug-induced Stevens-Johnson syndrome in the WHO ADR database. Pharmacoepidemiol Drug Saf 1992; 1: 11–8CrossRefGoogle Scholar
  14. 14.
    Mann RD. Drug safety alerts: a review of ‘Current Problem’. Pharmacoepidemiol Drug Saf 1992; 1: 269–79CrossRefGoogle Scholar
  15. 15.
    Meyboom RHB, Gribnau FWJ, Hekster YA, et al. Characteristics of topics in pharmacovigilance in the Netherlands. Clin Drug Invest 1996; 4: 207–19Google Scholar
  16. 16.
    Finney D. Statistical logic in the monitoring of reactions to therapeutic drugs. In: Inman WHW, editor. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press, 1986: 423–42Google Scholar
  17. 17.
    Gross TP. The analysis of postmarketing drug surveillance data at the U.S. Food and Drug Administration. In: Strom BL, Velo G, editors. Drug epidemiology and post-marketing surveillance. New York: Plenum Press, 1992: 1–7Google Scholar
  18. 18.
    Kramer MS. Clinical epidemiology and biostatistics. Berlin: Springer-Verlag, 1988CrossRefGoogle Scholar
  19. 19.
    Charlton BG. Attribution of causation in epidemiology: chain or mozaic? J Clin Epidemiol 1996; 49: 105–7PubMedCrossRefGoogle Scholar
  20. 20.
    Meyboom RHB, Egberts ACG, Hekster YA, et al. The role of causality assessment in pharmacovigilance. Drug Saf. In pressGoogle Scholar
  21. 21.
    Bradford Hill A. The environment and disease: association or causation? Proc R Soc Med 1965; 85: 295–300Google Scholar
  22. 22.
    Venning GR. Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems. BMJ 1983; 286: 458–60PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Ronald H. B. Meyboom
    • 1
  • Antoine C. G. Egberts
    • 1
    • 2
  • I. Ralph Edwards
    • 3
  • Yechiel A. Hekster
    • 4
  • Fred H. P. de Koning
    • 1
  • Frank W. J. Gribnau
    • 5
  1. 1.Netherlands Pharmacovigilance Foundation LAREBTilburgThe Netherlands
  2. 2.Department of Pharmacoepidemiology and PharmacotherapyUtrecht UniversityUtrechtThe Netherlands
  3. 3.WHO Collaborating Centre for International Drug MonitoringUppsalaSweden
  4. 4.Department of Clinical PharmacyNijmegen University Hospital St RadboudNijmegenThe Netherlands
  5. 5.Department of Clinical PharmacologyNijmegen University Hospital St RadboudNijmegenThe Netherlands

Personalised recommendations